Search

Your search keyword '"Theresa Davey"' showing total 23 results

Search Constraints

Start Over You searched for: Author "Theresa Davey" Remove constraint Author: "Theresa Davey" Search Limiters Available in Library Collection Remove constraint Search Limiters: Available in Library Collection
23 results on '"Theresa Davey"'

Search Results

1. T099: High efficacy and durability of second-line therapy with pembrolizumab, gemcitabine, vinorelbine, and liposomal doxorubicin in the phase II study for relapsed and refractory Hodgkin lymphoma

2. Individual-Centred Approaches to Accessibility in STEM Education

3. Influence and Sensitivity of Temperature and Microstructure on the Fluctuation of Creep Properties in Ni-Base Superalloy

4. Immune Signature of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin As Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma

5. The effect of oxygen impurities on the stability and structural properties of vacancy-ordered and -disordered ZrC

6. Stability and structural properties of vacancy-ordered and -disordered ZrC

7. A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomas

8. Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma

9. THE COMBINATION OF DUVELISIB AND ROMIDEPSIN (DR) IS HIGHLY ACTIVE AGAINST RELAPSED/REFRACTORY PERIPHERAL T‐CELL LYMPHOMA WITH LOW RATES OF TRANSAMINITIS: FINAL RESULTS

10. A PHASE II TRIAL OF REDUCED DOSE BRENTUXIMAB VEDOTIN FOR CUTANEOUS T‐CELL LYMPHOMAS

11. Influence and Sensitivity of Temperature and Microstructure on the Fluctuation of Creep Properties in Ni-Base Superalloy

12. Individual-Centred Approaches to Accessibility in STEM Education

13. Autologous Hematopoietic Cell Transplant Outcomes after Pembrolizumab Plus GVD As Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma

14. Phase II Study of Pembrolizumab Plus GVD As Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma

15. Abstract 4248: Multispectral immunofluorescence identifies pS6 as a biomarker of intrinsic resistance to ruxolitinib in patients with relapsed/refractory T-cell lymphomas

16. High Complete Response Rate Observed with Second-Line Chemo-Immunotherapy with Pembrolizumab and GVD (Gemcitabine, Vinorelbine, and Liposomal Doxorubicin) in Relapsed and Refractory Classical Hodgkin Lymphoma

17. A Phase II, Multicenter Study of High Dose Chemotherapy with Autologous Stem Cell Transplant Followed By Maintenance Therapy with Romidepsin for T-Cell Lymphoma

18. Final Results of a Phase II Biomarker-Driven Study of Ruxolitinib in Relapsed and Refractory T-Cell Lymphoma

19. Long-Term Follow-up Confirms Durability of Single-Agent Brentuximab Vedotin As Pre-Transplant Salvage for Classical Hodgkin Lymphoma

20. Durable Responses Observed with JAK Inhibition in T-Cell Lymphomas

21. The Combination of Duvelisib, a PI3K-δ,γ Inhibitor, and Romidepsin Is Highly Active in Relapsed/Refractory Peripheral T-Cell Lymphoma with Low Rates of Transaminitis: Results of Parallel Multicenter, Phase 1 Combination Studies with Expansion Cohorts

22. In Vitro, In Vivo, and Parallel Phase I Evidence Support the Safety and Activity of Duvelisib, a PI3K-δ,γ Inhibitor, in Combination with Romidepsin or Bortezomib in Relapsed/Refractory T-Cell Lymphoma

23. Improved method of calculatingab initiohigh-temperature thermodynamic properties with application to ZrC

Catalog

Books, media, physical & digital resources